Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Xadago“
Suchtreffer
Begriffe & Kennungen
Xadago
Eintrag öffnenXadago · 4.1 Therapeutic indications · 1
Eintrag öffnenXadago · 4.3 Contraindications · 1
Eintrag öffnenXadago · 4.3 · Hypersensitivity to the active substance or to any of the excipients (see section 6.1). Concomitant treatment
Eintrag öffnenXadago · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenXadago · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenXadago · 4.5 · 4 Serious adverse reactions have been reported with the concomitant use of selective serotonin reuptake inhibi
Eintrag öffnenXadago · 4.5 · Antidepressants The concomitant use of safinamide and fluoxetine or fluvoxamine should be avoided (see section
Eintrag öffnenXadago · 4.5 · Dextromethorphan There have been reports of medicinal product interactions with the concomitant use of dextrom
Eintrag öffnenXadago · 4.5 · In vivo and in vitro pharmacodynamic drug interactions
Eintrag öffnenXadago · 4.5 · In vivo and in vitro pharmacokinetic drug interactions
Eintrag öffnenXadago · 4.5 · Interaction studies have only been performed in adults.
Eintrag öffnenXadago · 4.5 · MAO inhibitors and pethidine Safinamide must not be administered along with other MAO inhibitors (including mo
Eintrag öffnenXadago · 4.5 · Paediatric population
Eintrag öffnenXadago · 4.5 · Safinamide inhibits OCT1 in vitro at clinically relevant portal vein concentrations. Therefore, caution is nec
Eintrag öffnenXadago · 4.5 · Safinamide is almost exclusively eliminated via metabolism, largely by high capacity amidases that have not ye
Eintrag öffnenXadago · 4.5 · Safinamide may transiently inhibit BCRP in vitro. In drug-drug-interaction studies in human, a weak interactio
Eintrag öffnenXadago · 4.5 · Serious adverse reactions have been reported with the concomitant use of pethidine and MAO inhibitors. As this
Eintrag öffnenXadago · 4.5 · The metabolite NW-1153 is a substrate for OAT3 at clinically relevant concentrations. Medicinal products that
Eintrag öffnenXadago · 4.5 · There have been reports of medicinal product interactions with the concomitant use of MAO inhibitors and sympa
Eintrag öffnen